These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25705681)

  • 1. Detecting key genes regulated by miRNAs in dysfunctional crosstalk pathway of myasthenia gravis.
    Cao Y; Wang J; Zhang H; Tian Q; Chen L; Ning S; Liu P; Sun X; Lu X; Song C; Zhang S; Xiao B; Wang L
    Biomed Res Int; 2015; 2015():724715. PubMed ID: 25705681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation.
    Le Panse R; Berrih-Aknin S
    Curr Opin Neurol; 2013 Oct; 26(5):569-76. PubMed ID: 23995274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myasthenia gravis and the neuromuscular junction.
    Querol L; Illa I
    Curr Opin Neurol; 2013 Oct; 26(5):459-65. PubMed ID: 23945282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune mechanisms in myasthenia gravis.
    Cavalcante P; Bernasconi P; Mantegazza R
    Curr Opin Neurol; 2012 Oct; 25(5):621-9. PubMed ID: 22941261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review on the Role of Non-Coding RNAs in the Pathogenesis of Myasthenia Gravis.
    Ghafouri-Fard S; Azimi T; Hussen BM; Taheri M; Jalili Khoshnoud R
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis.
    Cao Y; Lu X; Wang J; Zhang H; Liu Z; Xu S; Wang T; Ning S; Xiao B; Wang L
    Int J Mol Med; 2017 Feb; 39(2):268-278. PubMed ID: 28075449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement deposition at the neuromuscular junction in seronegative myasthenia gravis.
    Hoffmann S; Harms L; Schuelke M; Rückert JC; Goebel HH; Stenzel W; Meisel A
    Acta Neuropathol; 2020 Jun; 139(6):1119-1122. PubMed ID: 32157386
    [No Abstract]   [Full Text] [Related]  

  • 8. Insights in the autoimmunity of myasthenia gravis.
    De Baets MH
    Autoimmunity; 2010 Aug; 43(5-6):341-3. PubMed ID: 20380585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on "Detecting Key Genes Regulated by miRNAs in Dysfunctional Crosstalk Pathway of Myasthenia Gravis".
    Le Panse R
    Biomed Res Int; 2017; 2017():6950308. PubMed ID: 28271070
    [No Abstract]   [Full Text] [Related]  

  • 10. Myasthenia gravis and related disorders: Pathology and molecular pathogenesis.
    Ha JC; Richman DP
    Biochim Biophys Acta; 2015 Apr; 1852(4):651-7. PubMed ID: 25486268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global pathway view analysis of microRNA clusters in myasthenia gravis.
    Bo C; Wang J; Zhang H; Cao Y; Lu X; Wang T; Wang Y; Li S; Kong X; Sun X; Liu Z; Ning S; Wang L
    Mol Med Rep; 2019 Mar; 19(3):2350-2360. PubMed ID: 30664201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to: Comment on "Detecting Key Genes Regulated by miRNAs in Dysfunctional Crosstalk Pathway of Myasthenia Gravis".
    Cao Y; Wang J; Zhang H; Tian Q; Chen L; Ning S; Liu P; Sun X; Lu X; Song C; Zhang S; Xiao B; Wang L
    Biomed Res Int; 2017; 2017():5359434. PubMed ID: 28884124
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic and antibody-mediated channelopathies at the neuromuscular junction.
    Vincent A; Mills K
    Electroencephalogr Clin Neurophysiol Suppl; 1999; 50():250-8. PubMed ID: 10689470
    [No Abstract]   [Full Text] [Related]  

  • 14. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myasthenia and the neuromuscular junction.
    Gilhus NE
    Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes.
    Luo Z; Li Y; Liu X; Luo M; Xu L; Luo Y; Xiao B; Yang H
    BMC Med Genomics; 2015 Mar; 8():13. PubMed ID: 25889429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
    Baggi F; Antozzi C; Toscani C; Cordiglieri C
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis.
    Huijbers MG; Lipka AF; Plomp JJ; Niks EH; van der Maarel SM; Verschuuren JJ
    J Intern Med; 2014 Jan; 275(1):12-26. PubMed ID: 24215230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Autoantibodies detected in acetylcholine receptor antibody-negative myasthenia gravis].
    Ohta R; Motomura M
    Rinsho Byori; 2014 Mar; 62(3):255-60. PubMed ID: 24800501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.